Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mancini

Showing results (361-370 of 384) with videos related to

Pageof 39
Sort By:
Pediatric Dermatology|February 12, 2016
Infantile Hemangiomas in Twins: A Prospective Cohort StudyM Fernanda Greco, Ilona J Frieden, Beth A Drolet, et al.
The Journal of Investigative Dermatology|January 24, 2015
Development and Validation of a Quality-of-Life Instrument for Infantile HemangiomasSarah L Chamlin, Anthony J Mancini, Jin-Shei Lai, et al.
Surgical Endoscopy|October 25, 2017
Prospective evaluation of poly-4-hydroxybutyrate mesh in CDC class I/high-risk ventral and incisional hernia repair: 18-month follow-upJohn Scott Roth, Gary J Anthone, Don J Selzer, et al.
Archives of Dermatology|February 22, 2012
Measuring the severity of infantile hemangiomas: instrument development and reliabilityAnita N Haggstrom, Jennifer L Beaumont, Jin-She Lai, et al.
The British Journal of Dermatology|April 9, 2024
Midfacial toddler excoriation syndrome (MiTES): case series, diagnostic criteria and evidence for a pathogenic mechanismNivedita Sarveswaran, Yunisa Pamela, Akhila A N Reddy, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2D Riendeau, M D Percival, C Brideau, et al.
JAMA Dermatology|June 16, 2021
Association of Demographic Factors and Infantile Hemangioma Characteristics With Risk of PHACE SyndromeColleen H Cotton, Jusleen Ahluwalia, Daniel M Balkin, et al.
JAMA Dermatology|December 12, 2019
Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE SyndromeGerilyn M Olsen, Leanna M Hansen, Nicole S Stefanko, et al.
Pageof 39

Showing results (361-370 of 384) with videos related to

Sort By:
Pageof 39
Pediatric Dermatology|February 12, 2016
Infantile Hemangiomas in Twins: A Prospective Cohort StudyM Fernanda Greco, Ilona J Frieden, Beth A Drolet, et al.
The Journal of Investigative Dermatology|January 24, 2015
Development and Validation of a Quality-of-Life Instrument for Infantile HemangiomasSarah L Chamlin, Anthony J Mancini, Jin-Shei Lai, et al.
Surgical Endoscopy|October 25, 2017
Prospective evaluation of poly-4-hydroxybutyrate mesh in CDC class I/high-risk ventral and incisional hernia repair: 18-month follow-upJohn Scott Roth, Gary J Anthone, Don J Selzer, et al.
Archives of Dermatology|February 22, 2012
Measuring the severity of infantile hemangiomas: instrument development and reliabilityAnita N Haggstrom, Jennifer L Beaumont, Jin-She Lai, et al.
The British Journal of Dermatology|April 9, 2024
Midfacial toddler excoriation syndrome (MiTES): case series, diagnostic criteria and evidence for a pathogenic mechanismNivedita Sarveswaran, Yunisa Pamela, Akhila A N Reddy, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2D Riendeau, M D Percival, C Brideau, et al.
JAMA Dermatology|June 16, 2021
Association of Demographic Factors and Infantile Hemangioma Characteristics With Risk of PHACE SyndromeColleen H Cotton, Jusleen Ahluwalia, Daniel M Balkin, et al.
JAMA Dermatology|December 12, 2019
Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE SyndromeGerilyn M Olsen, Leanna M Hansen, Nicole S Stefanko, et al.
Pageof 39